Xanthine oxidase-IN-6
Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (XOD) inhibitor with an IC50 value of 1.37 µM. Xanthine oxidase-IN-6 shows strong anti-hyperuricemia and renal protective activity.
For research use only. We do not sell to patients.
- Formula: C29H34N2O15
- Molecular Weight:650.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
XOD 1.37 μM (IC50) |
NF-κB |
TLR4 |
Xanthine oxidase-IN-6 (Compound 6c) is a mixed-type XOD inhibitor, preferentially bound to the free enzyme and not the enzyme substrate complex[1].
Xanthine oxidase-IN-6 is stable in simulated gastrointestinal digestion, with hydrolysis half-life more than 4 h[1].
Xanthine oxidase-IN-6 (0-100 µM) exhibits an obvious anti-inflammatory effect by reducing the level of inflammatory factors (TGF-β, TNF-α and IL-1β) in a dose-dependent manner[1].
Xanthine oxidase-IN-6 (0-100 µM, 48 h) inhibits HK-2 cell epithelial mesenchymal transition under high level of uric acid[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HK-2 cells
-
Concentration:12.5, 25, 50, and 100 µM
-
Incubation Time:48 h
-
Result:Reduced the protein levels of α-SMA and Collagen I in a dose-dependent manner
Xanthine oxidase-IN-6 (0-20 mg/kg; i.g.; once daily for 2 weeks) effectively reduces renal fibrosis and inflammation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, weight 20 ± 2 g). Hyperuricemic mouse model established by administering 0.5% CMC-Na (10 mL/kg), adenine (200 mg/kg) and potassium oxonate (500 mg/kg); oral gavage once daily for 2 or 4 weeks[1].
-
Dosage:5, 10 and 20 mg/kg
-
Administration:Gavage, once daily for 2 weeks
-
Result:Effectively decreased the levels of SUA, Cr, and BUN, effectively inhibited XOD activity and urate accumulation in a dose-dependent manner. Remarkedly improved the morphologic lesions with less fibrosis in the interstitium. Reduced the production of multiple cytokines (TNF-α, IL-8, and IL-1β). Reduced the expression of α-SMA, collagen I, TLR4, NF-κB, IκBα and TNF-α.
Chemical Information
-
Molecular Weight 650.58
-
Formula C29H34N2O15
-
SMILES
[H][C@]12CC=C([C@]1(C(OC=C2C(NC3=NC=CO3)=O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4OC(C)=O)OC(C)=O)OC(C)=O)COC(C)=O)[H])COC(C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Xanthine oxidase-IN-6 Related Classifications
HY-146560 Related Classifications
Powered by Bioz